Cited 11 times in
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2024-03-22T06:00:38Z | - |
dc.date.available | 2024-03-22T06:00:38Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1540-1405 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198329 | - |
dc.description.abstract | BACKGROUND: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment-induced gonadotoxicity. PATIENTS AND METHODS: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the biological window of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy). RESULTS: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33-42 years). AMH values at the 3 time points differed significantly (P<.001). At baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56-2.62 ng/mL). At week 2, a small but significant reduction in AMH levels was observed (median, 1.10 ng/mL; IQR, 0.45-2.09 ng/mL; P<.001). At surgery, a larger significant decline in AMH levels was observed (median, 0.01 ng/mL; IQR, 0.01-0.03 ng/mL; P<.001). Although the type of anti-HER2 treatment (trastuzumab and/or lapatinib) did not seem to impact the results, age and pretreatment ovarian reserve had a major influence on treatment-induced gonadotoxicity risk. CONCLUSIONS: This NeoALTTO biomarker analysis showed that anti-HER2 therapies alone had limited gonadotoxicity but that the addition of weekly paclitaxel resulted in marked AMH decline with possible negative implications for subsequent ovarian function and fertility. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Harborside Press | - |
dc.relation.isPartOf | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Biomarkers | - |
dc.subject.MESH | Breast Neoplasms* / drug therapy | - |
dc.subject.MESH | Breast Neoplasms* / surgery | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lapatinib / therapeutic use | - |
dc.subject.MESH | Ovarian Reserve* | - |
dc.subject.MESH | Paclitaxel / adverse effects | - |
dc.title | Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Matteo Lambertini | - |
dc.contributor.googleauthor | Marcello Ceppi | - |
dc.contributor.googleauthor | Richard A Anderson | - |
dc.contributor.googleauthor | David A Cameron | - |
dc.contributor.googleauthor | Marco Bruzzone | - |
dc.contributor.googleauthor | Maria Alice Franzoi | - |
dc.contributor.googleauthor | Claudia Massarotti | - |
dc.contributor.googleauthor | Sarra El-Abed | - |
dc.contributor.googleauthor | Yingbo Wang | - |
dc.contributor.googleauthor | Christophe Lecocq | - |
dc.contributor.googleauthor | Paolo Nuciforo | - |
dc.contributor.googleauthor | Rebecca Rolyance | - |
dc.contributor.googleauthor | Lajos Pusztai | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Maria Maddalena Latocca | - |
dc.contributor.googleauthor | Luca Arecco | - |
dc.contributor.googleauthor | Barbara Pistilli | - |
dc.contributor.googleauthor | Kathryn J Ruddy | - |
dc.contributor.googleauthor | Alberto Ballestrero | - |
dc.contributor.googleauthor | Lucia Del Mastro | - |
dc.contributor.googleauthor | Fedro A Peccatori | - |
dc.contributor.googleauthor | Ann H Partridge | - |
dc.contributor.googleauthor | Cristina Saura | - |
dc.contributor.googleauthor | Michael Untch | - |
dc.contributor.googleauthor | Martine Piccart | - |
dc.contributor.googleauthor | Serena Di Cosimo | - |
dc.contributor.googleauthor | Evandro de Azambuja | - |
dc.contributor.googleauthor | Isabelle Demeestere | - |
dc.identifier.doi | 10.6004/jnccn.2022.7065 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J03857 | - |
dc.identifier.eissn | 1540-1413 | - |
dc.identifier.pmid | 36634607 | - |
dc.identifier.url | https://jnccn.org/view/journals/jnccn/21/1/article-p33.xml | - |
dc.subject.keyword | Anti-Mullerian hormone | - |
dc.subject.keyword | anti-HER2 therapy | - |
dc.subject.keyword | breast cancer | - |
dc.subject.keyword | gonadotoxicity | - |
dc.subject.keyword | paclitaxel | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 33 | - |
dc.citation.endPage | 41.e16 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, Vol.21(1) : 33-41.e16, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.